Mustang Bio (MBIO) vs Redhill Biopharma (RDHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Mustang Bio is the larger company by market cap ($2.7 million vs $2.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBIO | RDHL |
|---|---|---|
| Share price | $0.3541 | $0.281 |
| Market cap | $2.69M | $2.50M |
| 1-day change | -4.30% | -13.08% |
| Forward P/E | — | 9.37 |
| EPS (TTM) | $-0.51 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.04M |
| Revenue growth (YoY) | — | +23.17% |
| Net income (latest FY) | $-1.92M | $-8.27M |
| Gross margin | — | 60.31% |
| Operating margin | — | -181.69% |
| Net margin | — | -102.80% |
| 52-week high | $1.43 | $1.60 |
| 52-week low | $0.35 | $0.281 |
| Distance from 52-week high | -75.24% | -82.44% |
| Average volume | 33.87K | 2.08M |
| Shares outstanding | 6.74M | 8.89M |
| Employees | 4 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Redhill Biopharma
RDHL stock →RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
MBIO vs RDHL FAQ
Which is bigger, Mustang Bio or Redhill Biopharma?
Mustang Bio (MBIO) is larger, with a market capitalization of $2.69M compared with $2.50M for Redhill Biopharma (RDHL).
Are Mustang Bio and Redhill Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.